Lundbeck carries on Rexulti study after new analysis

After having received a new interim analysis, Lundbeck and its partner Otsuka have decided to keep going with a phase III study with the drug Rexulti for treating Alzheimer's symptoms.

Photo: Jens Dresling

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Published: 13.04.21 at 12:10

Danish pharmaceutical company Lundbeck and its partner Japanese pharmaceutical firm Otsuka have long been anticipating the results of their phase III trial with Rexulti, or brexpiprazole, for treating agitation in patients suffering from the dementia disease Alzheimer's.

Now, some of the results have been unveiled.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Ambu board had started headhunting process long before firing of CEO

With Chairman of Ambu Jørgen Jensen at the helm, the company's board decided to lay off chief executive Juan Jose Gonzalez on Thursday | Foto: Ida Munch/ERH

Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.

Nine new drugs recommended for approval by CHMP at May meeting

Foto: Peter Dejong/AP/Ritzau Scanpix

During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.

Britt Meelby Jensen wants to rebuild trust in Ambu

Britt Meelby Jensen, new CEO of Ambu | Foto: Novo Holdings / PR

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

Today, Juan Jose Gonzalez steps down from his role as chief executing of Ambu | Foto: Ambu/PR

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Top news from MedWatch this week

Miss anything?

Further reading

Related articles